Maxigen Biotech Inc. 和康生物科技股份有限公司

 Maxigen Biotech Inc. (MBI) was formed by a group of entrepreneurs and scientists in December 1998. With headquarters inTaipei, Taiwan, MBI has utilized its core competence in biopolymers and developed a broad range of applications in areas such as medical devices and skincare products.  MBI specializes in the developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products.  Our major shareholders include GIH Group, Mega International Commercial Bank, First Financial Holding, and Nasdaq-listed medical device company – NuVasive Inc.
 
 

MBI has developed a rich pipeline of biomedical products which consists of FormaGraft®, Foramic®, ArtiAid®, ophthalmic viscoelastic - ViscAid®, and surgical and dental wound dressing - SurgiAid®.  In accordance to the growing trend of minimally invasive surgery, MBI has also developed several biomedical applications, such as injectable bone graft and anti-adhesive... [more]